Here's What Analysts Are Forecasting For COSMOS Pharmaceutical Corporation (TSE:3349) After Its Annual Results

Last week, you might have seen that COSMOS Pharmaceutical Corporation (TSE:3349) released its annual result to the market. The early response was not positive, with shares down 5.7% to JP¥8,939 in the past week. It was a credible result overall, with revenues of JP¥1.0t and statutory earnings per share of JP¥391 both in line with analyst estimates, showing that COSMOS Pharmaceutical is executing in line with expectations. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

Following the latest results, COSMOS Pharmaceutical's twelve analysts are now forecasting revenues of JP¥1.08t in 2026. This would be a modest 6.6% improvement in revenue compared to the last 12 months. Per-share earnings are expected to rise 6.5% to JP¥416. In the lead-up to this report, the analysts had been modelling revenues of JP¥1.08t and earnings per share (EPS) of JP¥418 in 2026. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.

Check out our latest analysis for COSMOS Pharmaceutical

It will come as no surprise then, to learn that the consensus price target is largely unchanged at JP¥9,756. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. The most optimistic COSMOS Pharmaceutical analyst has a price target of JP¥12,000 per share, while the most pessimistic values it at JP¥8,000. These price targets show that analysts do have some differing views on the business, but the estimates do not vary enough to suggest to us that some are betting on wild success or utter failure.

Of course, another way to look at these forecasts is to place them into context against the industry itself. It's pretty clear that there is an expectation that COSMOS Pharmaceutical's revenue growth will slow down substantially, with revenues to the end of 2026 expected to display 6.6% growth on an annualised basis. This is compared to a historical growth rate of 8.5% over the past five years. Juxtapose this against the other companies in the industry with analyst coverage, which are forecast to grow their revenues (in aggregate) 1.8% per year. So it's pretty clear that, while COSMOS Pharmaceutical's revenue growth is expected to slow, it's still expected to grow faster than the industry itself.

The Bottom Line

The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. The consensus price target held steady at JP¥9,756, with the latest estimates not enough to have an impact on their price targets.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have estimates - from multiple COSMOS Pharmaceutical analysts - going out to 2028, and you can see them free on our platform here.

We also provide an overview of the COSMOS Pharmaceutical Board and CEO remuneration and length of tenure at the company, and whether insiders have been buying the stock, here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.